Digitisation | April 19, 2024
Dr. Reddy’s launches integrated care plan to manage irritable bowel syndrome
Around 7% of the Indian population suffers from IBS
Around 7% of the Indian population suffers from IBS
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
Submission based on results from pivotal phase III trial showing all primary endpoints met
Ofloxacin Ophthalmic Solution USP 0.3% is indicated for treatment of eye infections caused during the conditions of conjunctivitis and corneal ulcers
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
Longest survival follow-up ever reported for immunotherapy treatment in this setting
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally
CHL is strengthening its play in the fast-growing beauty and personal care sector
Subscribe To Our Newsletter & Stay Updated
